| Trial ID # | NCT03673124 |
| Phase | II |
| Drug Class | Cell Cycle Inhibitors: CDK4/6 |
| Drug Name | Ribociclib |
| Alternate Drug Names | Kisqali, CDK4/6 Inhibitor LEE011, LEE011 |
| Drugs in Trial | Letrozole, Ribociclib |
| Eligible Participant | Recurrent low grade serous ovarian cancer |
| Patients Enrolled | 48, median 1 prior therapy (0-3) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, evaluated per RECIST |
| Efficacy | ORR: 23% (11PR, n=42) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of letrozole plus ribociclib demonstrates promising activity in women with recurrent LGSOC |
| Reference | Slomovitz B et al. GOG 3026 A Phase II Trial of Letrozole + Ribociclib in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum: A GOG Foundation Study. SGO (2023) abstract 10 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.